Commonwealth Retirement Investments LLC Has $2.06 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Commonwealth Retirement Investments LLC grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 8.1% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 24,510 shares of the biopharmaceutical company’s stock after buying an additional 1,828 shares during the quarter. Commonwealth Retirement Investments LLC’s holdings in Gilead Sciences were worth $2,055,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in GILD. GSA Capital Partners LLP acquired a new position in Gilead Sciences during the first quarter worth $462,000. Quantbot Technologies LP bought a new position in Gilead Sciences during the 1st quarter valued at about $573,000. Koshinski Asset Management Inc. bought a new position in Gilead Sciences during the 1st quarter valued at about $217,000. TD Asset Management Inc grew its stake in Gilead Sciences by 2.5% during the first quarter. TD Asset Management Inc now owns 1,055,180 shares of the biopharmaceutical company’s stock worth $77,292,000 after buying an additional 25,523 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System increased its holdings in shares of Gilead Sciences by 5.3% during the first quarter. State Board of Administration of Florida Retirement System now owns 1,439,858 shares of the biopharmaceutical company’s stock worth $105,470,000 after buying an additional 71,921 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Insider Transactions at Gilead Sciences

In related news, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the sale, the insider now owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the transaction, the insider now owns 78,127 shares of the company’s stock, valued at $6,545,480.06. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the sale, the insider now directly owns 100,189 shares in the company, valued at approximately $8,398,843.87. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 56,947 shares of company stock valued at $4,968,674 in the last ninety days. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Trading Down 0.6 %

Shares of Gilead Sciences stock traded down $0.54 during trading hours on Tuesday, hitting $96.49. The company’s stock had a trading volume of 1,156,930 shares, compared to its average volume of 7,022,184. The stock has a 50 day moving average of $85.66 and a 200 day moving average of $75.37. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $98.90. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.11 and a quick ratio of 0.95. The company has a market capitalization of $120.13 billion, a PE ratio of 1,078.11, a price-to-earnings-growth ratio of 3.36 and a beta of 0.17.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. The business’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.29 earnings per share. Analysts predict that Gilead Sciences, Inc. will post 4.34 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Investors of record on Friday, December 13th will be issued a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.19%. Gilead Sciences’s payout ratio is presently 3,422.22%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on GILD shares. Robert W. Baird increased their price target on Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a research report on Thursday, November 7th. Oppenheimer increased their price objective on shares of Gilead Sciences from $95.00 to $105.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. Leerink Partnrs upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 21st. Sanford C. Bernstein assumed coverage on shares of Gilead Sciences in a research note on Thursday, October 17th. They set an “outperform” rating and a $105.00 price target on the stock. Finally, Royal Bank of Canada boosted their price objective on shares of Gilead Sciences from $75.00 to $81.00 and gave the stock a “sector perform” rating in a research report on Thursday, November 7th. Eleven analysts have rated the stock with a hold rating, ten have issued a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $91.50.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.